JP4837734B2 - 痴呆及び神経炎症性疾患の検出のためのCSF検出invitro方法 - Google Patents
痴呆及び神経炎症性疾患の検出のためのCSF検出invitro方法 Download PDFInfo
- Publication number
- JP4837734B2 JP4837734B2 JP2008521892A JP2008521892A JP4837734B2 JP 4837734 B2 JP4837734 B2 JP 4837734B2 JP 2008521892 A JP2008521892 A JP 2008521892A JP 2008521892 A JP2008521892 A JP 2008521892A JP 4837734 B2 JP4837734 B2 JP 4837734B2
- Authority
- JP
- Japan
- Prior art keywords
- dementia
- pct
- measured
- measurement
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/585—Calcitonins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/557—Immunoassay; Biospecific binding assay; Materials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
AKIYAMA H. AND THE NEUROINFLAMMATION WORKING GROUP (2000). Inflammation and Alzheimer. Neuroblology of Aging 21 : 383-421 ASSICOT M., GENDREL D., CARSIN H., RAYMOND J., GUILBAUD J., BOHUON C. (1993). High serum Procalcitonin concentrations in patients with sepsis and infection. Lancet 341: 515-518 BECKER K. L., NYLEN E. S., WHITE J. C, MUELLER B., SNIDER R. H. (2004) . Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors . Journal of Clinical Endocrinology and Metabolism 89: 1512-1525 CAPLAN L., SCHOENE W. C. (1978). Clinical features of subcortical arteriosclerotic encephalopathy (Binswanger's disease) . Neurology 28: 1206-1215 DANDONA P., NIX D., WILSON M. F., ALJADA A., LOVE J., ASSICOT M., BOHUON C. (1994). Procalcitonin increase after endotoxin injection in normal subjects. Journal of Clinical Endocrinolgy and Metabolism 79: 1605-1608 GELDMACHER D. S. (2004). Dementia with lewy bodies : diagnosis and clinical approach. Cleveland clinic Journal of Medicine 71: 789-800 GENDREL D., ASSICOT M., RAYMOND J., MOULIN F., FRANCOUAL C, BADOUAL J., BOHOUN C. (1996). Procalcitonin as a marker for the early diagnosis of neonatal infection. Journal of Pediatrics 128: 570-573 GENDREL D., RAYMOND J., ASSICOT M., MOULIN F., INIGUEZ J.L., LEBON P., BOHUON C. (1997). Measurement of Procalcitohin levels in children with bacterial or viral meningitis. Clinical Infectious Diseases 24: 1240-1242 HACHINSKI V. C, LASSEN N. A., MARSHALL J. (1974). MuIti-infarct dementia: a cause of mental deterioration in the elderly. Lancet 2: 207-209 HAN Y. Y., CARCILLO J. A., RUPPELL R. A., ADELSON P. D., WISNIEWSKI S. R., BELL M. I., JANESKO K. L., MARION D. W., KOCHANEK P. M. (2002). Cerebrospinal fluid Procalcitonin and severe traumatic brain injury in children. Pediatric Critical Care Medicine 3: 39-44 HOLMES C, CAIRNS N., LANTOS P., MANN A. (1999). VaIidity of current clinical criteria for Alzheimer' s disease, vascular dementia and dementia with lewy bodies. British Journal of Psychiatry 174: 45-50 JEREB M., MULOVIC I., HOJKER S., STRLE F. (2001). Predictive value of serum and cerebrospinal fluid Procalcitonin levels for the diagnosis of bacterial meningitis. Infection 29: 209-212 KATSUSE 0., ISEKI E., KOSAKA K. (2003). Immunohistochemical study of the expression of cytokines and nitric oxide synthases in brains of patients with dementia with lewy bodies . Neuropathology 23: 9-15 LOTRIC-FURLAN S., MARASPIN-CARMAN V., CIMPERMAN J., ORINE K., STOPAR T., STRLE F. (2002). Procalcitonin levels in patients with Lyme borreliosis. Wiener Klinische Wochenschrift 114: 530-532 MACKENZIE I. R. (2000). Activated microglia in dementia with lewy bodies. Neurology 55: 132-134 MACKENZIE I. R. (2001). Cortical Inflammation in Dementia With Lewy Bodies, Arch. Neurol . 58: 519-520 MCKEITH 1. G., GALASKO D., KOSAKA K., PERRY E. K., DICKSON D. W., HANSEN L. A., SALMON D. P., LOWE J., MIRRA S. S., BYRNE E. J., LENNOX G., QUINN N. P., EDWARDSON J. A., INCE P. G., BERGERON C, BURNS A., MILLER B . L . , LOVESTONE S . , COLLERTON D . , JANSEN E . N . , BALLARD C, DE VOS R. A., WILCOCK G. K., JELLINGER K. A., PERRY R. H. (1996). Consensus guidelines for the clinical and pathologic diagnosis of dementia with lewy bodies (DLB) : report of the consortium on DLB international Workshop. Neurology 47: 1113-1124 MCKEITH I. G., O'BRIEN J. T., BALLARD C. (1999). Diagnosing dementia with lewy bodies. Lancet 354: 1227-1228 MCKEITH I. G. (2002). Dementia with lewy bodies. British Journal of Psychiatry 180: 144-147 MORGENTHALER N. G., STRUCK J., FISCHER-SCHULZ C, BERGMANN A. (2002) . Sensitive immunoluminometric assay for the detection of procalcitonin. Clinical Chemistry 48: 788-789 MUELLER B., BECKER K. L., SCHACHINGER H., RICKENBACHER P. R., HUBER P. R., ZIMMERLI W., RITZ R. (2000). Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit . Critical Care Medicine 28: 977-983 O'CONNOR E., VENKATESH B., LIPMAN J., MASHONGONYIKA C, HALL J. (2001). Procalcitonin in critical Illness. Critical Care and Resuscitation 3: 236-243 RIZZU P., VAN SWIETEN J. C, JOOSSE M., HASEGAWA M., STEVENS M., TIBBEN A., NIERMEIJER M. F., HILLEBRAND M., RAVID R., OOSTRA B. A., GOEDERT M., VAN DUUN C. M., HEUTINK P. (1999) . High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. American Journal of Human Genetics 64: 414-421 SELKOE D. J. (2001). Alzheimer's disease: genes, proteins, and therapy. Physiological Reviews 81: 741-766 SHIMETANI N., SHIMETANI K., MORI M. (2001). Levels of three inflammation markers, C-reactive protein, serum amyloid A protein and procalcitonin, in the serum and cerebrospinal fluid of patients with meningitis. Scandinavian Journl of Clinical and Laboratory Investigation 61: 567-574 SJOGREN M., FOLKESSON S., BLENNOW K., TARKOWSKI E. (2004) . Increased intrathecal inflammatory activity in frontotemporal dementia: pathophysiological implications. Journal of Neurology and Neurosurgical Psychiatry 75: 1107-1111 SNIDER R. H. JR., NYLEN E. S., BECKER K. L. (1997). Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization. Journal of Investigative Medicine 45: 552-560 TARKOWSKI E. (2002). Cytokines in dementias. Current Drug Targets - Inflammation and Allergy 1: 193-200 TARKOWSKI E., LILJEROTH A. M., MINTHON L., TARKOWSKI A., WALLIN A., BLENNOW K. (2003). Cerebral pattern of pro- and anti-inflammatory cytokines in dementias. Brain Research Bulletin 61: 255-260 C. E. TEUNISSEN, J. DE VENTE, H. W. M. STEINBUSCH, C. DE BRUIJN (2002) , Biochemical markers related to Alzheimer' s dementia in serum and cerebrosoinal fluid. Neurobiology of Aging 23, 485-508 VARMA A. R . , SNOWDEN J . S . , LLOYD J . J . , TALBOT P . R . , MANN D. M., NEARY D. (1999). Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer' s disease and frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry 66: 184-188 WHANG K. T., STEINWALD P. M., WHITE J. C, NYLEN E. S., SNIDER R. H., SIMON G. L., GOLDBERG R. L., BECKER K. L. (1998) . Serum calcitonin precursors in sepsis and systemic inflammation. Journal of Clinical Endocrinolgy and Metabolism 83: 3296-3301 WHICHER I., BIENVENU J., MONNERET G. (2001). Procalcitonin as an acute phase marker. Annais of Clinical Biochemistry 38: 483-893 ZHUKAREVA V., VOGELSBERG-RAGAGLIA V., VAN DEERLIN V. M., BRUCE J., SHUCK T., GROSSMAN M., CLARK C. M., ARNOLD S. E., MASLIAH E., GALASKO D., TROJANOWSKI J. Q., LEE V. M. (2001) . Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia. Annais of Neurology 49: 165-175 SPENCER CA, LOPRESTI JS, PATEL A, GUTTLER RB, EIGEN A, SHEN D, GRAY D, NICOLOFF JT (1990) . Applications of a new chemiluminometric thyrotropin assay to subnormal measurement. J Clin Endocrinol Metab. 1990, 70(2) :453- 60
脳脊髄液におけるプロカルシトニンの測定を、非特許文献20に記載されたように実施した。しかしながら、凍結乾燥スタンダードを、ゼロの血清ではなくPBSに溶解した(1%BSAを有する)。
健康なコントロール患者の脳脊髄液で、LUMItest(登録商標)PCTsensitv(非特許文献20参照)を使用してプロカルシトニンを検出した。濃度は12から133ng/l(平均濃度50ng/l)の間の範囲に存在することを示すことが可能であった。健康な患者の血清における平均PCT濃度はわずか13.5ng/lとして測定されたため(非特許文献20)、健康な患者では約1:4の血液とCSFの間のPCT濃度勾配が存在する。
Claims (10)
- アルツハイマー痴呆(AD)、レヴィー小体を有する痴呆(DLB)、前頭側頭型痴呆(FTD)、及び各種の形態の血管痴呆を含む群から選択される痴呆及び非感染性の病因の慢性神経炎症性疾患の検出、重篤さの測定、並びにモニター及び予後のための痴呆の示差的検出の一部として実施される脳脊髄液(CSF)検出in vitro方法であって、プロカルシトニンの免疫活性(PCT免疫活性)の測定を、痴呆または神経炎症性疾患に罹患している患者、あるいはそのような疾患に罹患する疑いのある患者のCSFのサンプルで実施し、痴呆または神経炎症性疾患の存在、過程、重篤さ、及び治療の成功についての結論を、測定したPCT免疫活性から引き出し、それが健康なコントロール患者について典型的な値の閾値を超えるものであることを特徴とする方法。
- 前記PCT免疫活性が、l当たり100ng(100ng/lまたは100pg/ml)のPCTを超える機能的なアッセイ感度(FAS)を有する高感度PCT免疫アッセイの補助で測定されることを特徴とする、請求項1に記載の方法。
- 健康なコントロール患者について測定され、50pg/mlである平均値が、「神経炎症性疾患の疑いがある」との検出についての閾値として使用されることを特徴とする、請求項1または2に記載の方法。
- 前記PCT免疫活性の測定のためのPCT免疫アッセイが、カルシトニンの形成でPCTのタンパク質溶解性のプロセッシングにおいて形成された各種のメンバーのPCT部分ペプチドに位置する、またはカルシトニン配列を含まないPCT部分ペプチドに位置する完全PCTペプチドのセグメントに結合する二種類の抗体を使用するサンドイッチ免疫アッセイであることを特徴とする、請求項1から3のいずれか一項に記載の方法。
- 前記抗体の一方がカルシトニン配列のセグメントに結合し、前記抗体の他方がカタカルシン配列のセグメントに結合し、二種類の抗体の少なくとも一つがアフィニティー精製ポリクローナル抗体であることを特徴とする、請求項4に記載の方法。
- 測定されたPCT免疫活性の値が、痴呆の個々の形態について典型的な値の範囲に関連する示差的検出方法として実施され、考え得る痴呆の形態の一つの存在の可能性が測定されることを特徴とする、請求項1に記載の方法。
- 各臨床像について有益な少なくとも一つの更なる生化学的または生理学的なパラメーターが同時に測定され、測定された結果が痴呆または神経炎症性疾患の細かい検出のために評価される少なくとも二つの測定された変数のセットの形態で得られるマルチパラメーター測定の一部として実施されることを特徴とする、請求項1から6のいずれか一項に記載の方法。
- PCT免疫活性に加えて、前記マルチパラメーター測定の一部として、補体成分、サイトカイン、ケモカイン、血液凝固成分及び線維素溶解性因子、急性期のタンパク質、並びにフリーラジカル化合物からなる群から選択される、少なくとも一つの更なる炎症メディーエーターが測定されることを特徴とする、請求項7に記載の方法。
- 前記マルチパラメーター測定が、チップテクノロジー測定装置または免疫クロマトグラフィー測定装置によって同時の測定として実施されることを特徴とする、請求項7または8に記載の方法。
- 前記マルチパラメーター測定の複雑な測定結果の評価が、コンピュータープログラムの補助で実施されることを特徴とする、請求項7から9のいずれか一項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005034174A DE102005034174A1 (de) | 2005-07-21 | 2005-07-21 | Liquordiagnostisches in vitro Verfahren zur Diagnose von Demenz-Erkrankungen und neuroinflammatorischen Erkrankungen |
DE102005034174.8 | 2005-07-21 | ||
PCT/EP2006/007141 WO2007009789A1 (de) | 2005-07-21 | 2006-07-19 | Liquordiagnostisches in vitro verfahren zur diagnose von demenz-erkrankungen und neuroinflammatorischen erkrankungen |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009501917A JP2009501917A (ja) | 2009-01-22 |
JP4837734B2 true JP4837734B2 (ja) | 2011-12-14 |
Family
ID=36975312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008521892A Active JP4837734B2 (ja) | 2005-07-21 | 2006-07-19 | 痴呆及び神経炎症性疾患の検出のためのCSF検出invitro方法 |
Country Status (7)
Country | Link |
---|---|
US (2) | US20080206797A1 (ja) |
EP (1) | EP1904855B1 (ja) |
JP (1) | JP4837734B2 (ja) |
AT (1) | ATE483982T1 (ja) |
DE (2) | DE102005034174A1 (ja) |
ES (1) | ES2353722T3 (ja) |
WO (1) | WO2007009789A1 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005034174A1 (de) | 2005-07-21 | 2007-02-08 | B.R.A.H.M.S Ag | Liquordiagnostisches in vitro Verfahren zur Diagnose von Demenz-Erkrankungen und neuroinflammatorischen Erkrankungen |
DE102007009751A1 (de) | 2007-02-28 | 2008-09-04 | B.R.A.H.M.S Aktiengesellschaft | Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens |
CN110346577A (zh) | 2007-08-03 | 2019-10-18 | B.R.A.H.M.S 有限公司 | 降钙素原(pct)在患原发性非传染疾病的患者的风险分级和预后中的应用 |
EP2020603A1 (en) * | 2007-08-03 | 2009-02-04 | BRAHMS Aktiengesellschaft | Method for risk stratification in stable coronary artery disease |
US20100173417A1 (en) * | 2009-01-04 | 2010-07-08 | Lennart Minthon | Diagnostic method |
DK2419741T3 (da) | 2009-04-14 | 2019-11-04 | Brahms Gmbh | Risikovurdering af antibiotikabehandling af patienter, der lider af primær ikke-infektiøs sygdom, ved bestemmelse af niveauet af procalcitonin |
JP6009938B2 (ja) * | 2009-04-28 | 2016-10-19 | ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | プロカルシトニンの検出のためのイムノアッセイ |
WO2015104443A1 (es) * | 2014-01-08 | 2015-07-16 | Servicio Andaluz De Salud | Agentes moduladores de n-procalcitonina para la prevención y el tratamiento de enfermedades neurodegenerativas |
CN104792997B (zh) * | 2014-01-22 | 2017-07-11 | 天津汇滨生物科技有限公司 | 一种人降钙素原免疫检测试剂盒及其制备方法与应用 |
CN110514651A (zh) * | 2018-05-21 | 2019-11-29 | 博阳生物科技(上海)有限公司 | 一种化学发光免疫分析测定方法及使用该方法的系统、试剂盒 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001231555A (ja) * | 1999-12-22 | 2001-08-28 | Dade Behring Marburg Gmbh | 抗−プロカルシトニン抗体、その調製および使用 |
WO2004033448A2 (en) * | 2002-10-11 | 2004-04-22 | Proteotech, Inc. | Isolation, purification and synthesis of procyanidin b2 and uses thereof |
WO2004059293A2 (en) * | 2002-12-24 | 2004-07-15 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
JP2005512059A (ja) * | 2001-12-04 | 2005-04-28 | ベー・エル・アー・ハー・エム・エス・アクティエンゲゼルシャフト | S100bの測定による敗血症の診断方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1111050B1 (de) * | 1999-12-22 | 2007-03-14 | Dade Behring Marburg GmbH | Lösungen von humanem Procalcitonin |
US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
US20040253637A1 (en) * | 2001-04-13 | 2004-12-16 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
US7608406B2 (en) * | 2001-08-20 | 2009-10-27 | Biosite, Inc. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US20040209307A1 (en) * | 2001-08-20 | 2004-10-21 | Biosite Incorporated | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US20040219509A1 (en) * | 2001-08-20 | 2004-11-04 | Biosite, Inc. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
WO2005033327A2 (en) * | 2003-09-29 | 2005-04-14 | Biosite Incorporated | Methods and compositions for the diagnosis of sepsis |
US20050148029A1 (en) * | 2003-09-29 | 2005-07-07 | Biosite, Inc. | Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes |
DE102005034174A1 (de) | 2005-07-21 | 2007-02-08 | B.R.A.H.M.S Ag | Liquordiagnostisches in vitro Verfahren zur Diagnose von Demenz-Erkrankungen und neuroinflammatorischen Erkrankungen |
-
2005
- 2005-07-21 DE DE102005034174A patent/DE102005034174A1/de not_active Withdrawn
-
2006
- 2006-07-19 JP JP2008521892A patent/JP4837734B2/ja active Active
- 2006-07-19 WO PCT/EP2006/007141 patent/WO2007009789A1/de not_active Application Discontinuation
- 2006-07-19 AT AT06776308T patent/ATE483982T1/de active
- 2006-07-19 EP EP06776308A patent/EP1904855B1/de active Active
- 2006-07-19 ES ES06776308T patent/ES2353722T3/es active Active
- 2006-07-19 DE DE502006008028T patent/DE502006008028D1/de active Active
- 2006-07-19 US US11/996,213 patent/US20080206797A1/en not_active Abandoned
-
2015
- 2015-12-11 US US14/966,843 patent/US10921330B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001231555A (ja) * | 1999-12-22 | 2001-08-28 | Dade Behring Marburg Gmbh | 抗−プロカルシトニン抗体、その調製および使用 |
JP2005512059A (ja) * | 2001-12-04 | 2005-04-28 | ベー・エル・アー・ハー・エム・エス・アクティエンゲゼルシャフト | S100bの測定による敗血症の診断方法 |
WO2004033448A2 (en) * | 2002-10-11 | 2004-04-22 | Proteotech, Inc. | Isolation, purification and synthesis of procyanidin b2 and uses thereof |
WO2004059293A2 (en) * | 2002-12-24 | 2004-07-15 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2009501917A (ja) | 2009-01-22 |
US20160097782A1 (en) | 2016-04-07 |
WO2007009789A1 (de) | 2007-01-25 |
DE102005034174A1 (de) | 2007-02-08 |
DE502006008028D1 (de) | 2010-11-18 |
EP1904855B1 (de) | 2010-10-06 |
EP1904855A1 (de) | 2008-04-02 |
ES2353722T3 (es) | 2011-03-04 |
US10921330B2 (en) | 2021-02-16 |
US20080206797A1 (en) | 2008-08-28 |
ATE483982T1 (de) | 2010-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4837734B2 (ja) | 痴呆及び神経炎症性疾患の検出のためのCSF検出invitro方法 | |
Montagne et al. | Blood-brain barrier breakdown in the aging human hippocampus | |
Rota et al. | Increased intrathecal TGF-β1, but not IL-12, IFN-γ and IL-10 levels in Alzheimer’s disease patients | |
JP5241710B2 (ja) | 神経変性障害の診断および早期診断のためのinvitroマルチパラメータ測定法 | |
Dukic et al. | The role of human kallikrein 6, clusterin and adiponectin as potential blood biomarkers of dementia | |
EP2223119B1 (en) | Biomarkers and methods for diagnosing, predicting and/or prognosing sepsis and uses thereof | |
JP5005690B2 (ja) | 神経変性疾患の検出のためのinvitro方法 | |
JP2003521499A (ja) | タウオパチーの診断 | |
JP2010537200A (ja) | 改善されたアルツハイマー診断法 | |
Ingram et al. | Elevated plasma C4a levels in multiple sclerosis correlate with disease activity | |
JP2015505365A (ja) | アルツハイマー病を診断するための方法 | |
US8298784B2 (en) | In vitro procedure for diagnosis and early diagnosis of neurodegenerative diseases | |
Tsolaki et al. | Correlation of rCBF (SPECT), CSF tau, and congnitive function in patients with dementia of the Alzheimer's type, other types of dementia, and congrol subjects | |
Kalman et al. | Serum and cerebrospinal fluid cystatin C levels in vascular and Alzheimer's dementia | |
US20210270848A1 (en) | Method for diagnosing dementia or determining the risk of developing dementia | |
Wang et al. | Differential circulating levels of naturally occurring antibody to α-synuclein in Parkinson’s disease dementia, Alzheimer’s disease, and vascular dementia | |
Zheng et al. | Alpha-Synuclein species in oral mucosa as potential biomarkers for multiple system atrophy | |
Ernst et al. | Procalcitonin is elevated in the cerebrospinal fluid of patients with dementia and acute neuroinflammation | |
Blennow et al. | Cerebrospinal fluid ‘neuronal thread protein’comes from serum by passage over the blood-brain barrier | |
JP6611753B2 (ja) | アルツハイマー病の診断方法 | |
JPWO2010093001A1 (ja) | アルツハイマー病の診断方法および診断薬 | |
Profice et al. | Recurrent subarachnoid bleeding and superficial siderosis in a patient with histopathologically proven cerebral amyloid angiopathy | |
JP7461346B2 (ja) | 重度の外傷性脳損傷の血液バイオマーカー | |
Shen et al. | CSF interferon-β: A key player in Alzheimer’s disease pathogenesis and cognitive impairment | |
US20230273220A1 (en) | Methods for prediction, detection and monitoring of substanceuse disorders and/or an infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090410 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110112 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110419 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110607 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110830 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110928 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141007 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4837734 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |